NCT06321250View on ClinicalTrials.gov

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

April 30, 2027

Conditions
Renal Cell Carcinoma Metastatic
Interventions
DRUG

JMKX003948

Subjects will receive JMKX003948 tablets until disease progression

Trial Locations (1)

Unknown

RECRUITING

Beijing Caancer Hospital, Beijing

Sponsors

Lead Sponsor

Jemincare
All Listed Sponsors
collaborator

Zhejiang Hangyu Pharmaceutical Co., Ltd.

INDUSTRY

lead

Jemincare

INDUSTRY

NCT06321250 - A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter